Give me a higher, fully disclosed price over a lower quote with vague exclusions. That’s not a personal preference. It’s a quality call.
I’m a quality and compliance reviewer in the medical technology space. Before a clinical claim, training guide, or supplier agreement goes out the door, it crosses my desk. I’ve spent four years looking at the gap between what marketing promises and what the contract actually includes. In Q1 2024 alone, I sent back roughly 14% of first-run submissions because a line item was ambiguous, a claim was too broad, or a “standard” feature was quietly treated as an optional extra.
So when I say hidden fees are a quality defect, I mean it literally. The quote is part of the product. If it doesn’t tell the buyer what’s included, it isn’t ready for signature.
The Price at the Top Isn’t the Real Price
When I first started reviewing supplier documentation, I assumed the bottom-line price was the single most important number. I remember approving a quote because it came in 12% below the closest competitor. The vendor said the system was “complete.” It arrived without calibration fixtures and without a service coverage schedule. The vendor hadn’t lied, exactly. The fixtures were listed as optional accessories on page four. I just hadn’t asked what “complete” meant.
That was my rookie mistake. It cost us two weeks of delay and a separate purchase order.
In medical devices, the real cost is often hidden in plain sight:
- Instruments that come with the implant but aren’t included in the quoted case price.
- Loaner sets, reprocessing, and sterilization tracking.
- Software upgrades, service contracts, and response-time guarantees.
- Training for surgeons, OR staff, or lab technicians.
- Site preparation and installation for capital equipment.
- Disposables and consumables that have to be reordered for every case.
If those aren’t in the quote, the total cost of ownership is unknown. And an unknown total cost is a red flag, regardless of how trusted the brand name is.
A Brand Name Shouldn’t Replace Line-Item Detail
I see manufacturer names on quotes every day. When I see Zimmer Biomet, I think of a deep portfolio: orthopedic reconstruction, sports medicine, dental implants, ROSA robotic assistance, surgical instruments, and clinical education. That breadth is valuable. But a portfolio is not a purchase order.
If someone searches zimmer-biomet to find a product, the search engine gives them a starting point—not a contract. The same is true when a P.O. label reads something like Zimmer Biomet Apex Surgical. It tells me which channel or agreement generated the order. It does not tell me which catalog number, which instrument set, which sterilization requirements, or which training session is included. The label is helpful. The line items are proof.
Take sports medicine. A surgeon may ask for a Zimmer Biomet Sports Medicine anchor system for a shoulder repair. That’s a clear clinical preference, but it’s not enough for procurement. Which anchors? Suture tapes? Cannulas? Drill pins? Inserter handles? Is inventory consigned or purchased? What happens when a reusable instrument needs replacement? If the contract says “complete sports medicine set” without defining the set, I can’t verify it. And if I can’t verify it, I shouldn’t approve it.
A quality mindset demands itemization. It’s the only way to check expiration dates, lot numbers, and UDI traceability later.
Capital Equipment Is a System, Not a Single SKU
The transparency problem gets worse with capital equipment. The purchase price may look reasonable until you separate the device from the service plan and accessories.
Take an ultrasonic surgical aspirator. It has a console, handpieces, footswitches, irrigation tubing, and service requirements. If a quote says only “ultrasonic surgical aspirator” with one price, I don’t know whether the price covers the handpieces or just the base console. That distinction matters. Replacement handpieces are not cheap, and if they aren’t included, the total cost is materially higher than the headline number.
The same logic applies in diagnostics. A chemistry analyzer can have a very competitive base price while the reagent contract carries the real margin. That arrangement can be fair—but only if the annual reagent cost is visible from day one. I’ve seen labs choose an analyzer based on the hardware price and then discover the consumable cost was double the estimate. The analyzer wasn’t a bad product. The quote was just incomplete.
Even in imaging, buyers often ask the wrong first question. I sometimes get inquiries from clinics asking, “how does mammography work?” That’s a reasonable educational question. X-rays pass through breast tissue, different tissues attenuate the beam differently, and the detector creates an image. But that answer doesn’t tell you whether the quote includes the quality control phantom, technologist training, installation, or software upgrades. If a buyer focuses only on the imaging physics, they miss the real risk: unexpected operational costs after installation.
I’m not saying every buyer needs to be a biomedical engineer. I’m saying the vendor should be willing to document what’s included and what isn’t. If they can explain how the technology works, they can also explain what the total annual cost will look like.
Complexity Isn’t an Excuse for Opacity
I know what the defenders of vague quotes will say: medical device pricing is complicated. There are group purchasing contracts, rebates, tiered pricing, consignment agreements, and hospital-specific arrangements. Yes, all of that is real.
But complexity is not a reason to hide information. It’s a reason to be more precise.
In my experience, the vendors who are slow to answer “what’s NOT included” are usually the same vendors who struggle later when quality issues come up. It’s not that they’re trying to deceive anyone. It’s that they’re used to selling a brochure, not an auditable agreement. The moment a question touches a component list, service schedule, or installation requirement, the tone changes. That change is a pretty reliable signal.
On the flip side, I’ve seen sales reps who openly say, “the implant price is X, but the surgery center will need these instruments, and here’s the replacement cost if one is lost.” Those conversations are way more useful than the ones that end with, “trust me, it’s included.”
Buyers Create Some of the Problem
I also need to be honest: buyers can push vendors toward opacity.
If a hospital tells every distributor, “give me your lowest implant price and nothing else,” vendors learn to move costs somewhere else. The implant number comes down, and the service agreement, freight, or reprocessing charges go up. That’s not transparent. But it is a predictable response to a procurement process that rewards the lowest headline number.
That’s why I’m careful not to blame only manufacturers or distributors. The system gets less transparent when both sides treat the quote as a game.
Transparent pricing works best when buyers require it before they start negotiating. I’ve changed my own review process to include one simple requirement: show me the full itemized cost of ownership, including what is NOT included. If a supplier refuses to provide that, the quote fails my review. No exceptions.
The Bottom Line: Transparency Builds Trust, and Trust Is a Safety Feature
I am not saying higher prices are always better. I’m not saying brands don’t matter. A manufacturer’s clinical evidence, surgeon training, and post-market surveillance history absolutely matter. When I evaluate Zimmer Biomet products, for example, I look at the clinical data and the quality systems behind them. That’s important.
But brand trust only goes so far. The actual purchase agreement must be clear enough for a receiving clerk, a surgeon, an infection prevention specialist, and an accountant to all understand what they are approving.
Transparent pricing is not about making the seller look good. It’s about making the buyer safe from surprise costs and hidden assumptions. In a field where traceability, sterility, and specifications can affect patient outcomes, guesswork has no place in the purchasing process.
So here is my position, and I’m not going to soften it: an opaque quote is a quality failure. I would rather approve a higher price that is fully itemized than accept a lower price that leaves out the instruments, training, service, or consumables. The more transparent quote gives me something I can review. The vague one gives me a risk I can’t measure.
That’s not a tough sales conversation. That’s the difference between selling a device and protecting the people who use it.
Leave a Reply